A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

ClinicalTrials.gov ID: NCT06215118

Public ClinicalTrials.gov record NCT06215118. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

Study identification

NCT ID: NCT06215118
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Pfizer; Industry
Enrollment: 87 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Elranatamab Drug
Iberdomide Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 19, 2024
Primary completion: Apr 9, 2027
Completion: Mar 8, 2028
Last update posted: May 4, 2026

2024 – 2028

United States locations

U.S. sites: 15
U.S. states: 7
U.S. cities: 12

Facility	City	State	ZIP	Site status
University of Miami Hospital and Clinics Deerfield Beach	Deerfield Beach	Florida	33442	Not yet recruiting
University of Miami Hospital and Clinics	Miami	Florida	33136	Not yet recruiting
Indiana University Health University Hospital	Indianapolis	Indiana	46202	Recruiting
Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC)	Indianapolis	Indiana	46202	Recruiting
University of Maryland	Baltimore	Maryland	21201	Recruiting
Brigham and Women's Hospital	Boston	Massachusetts	02115	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Dana-Farber Cancer Institute - Chestnut Hill	Newton	Massachusetts	02459	Recruiting
University of Massachusetts Chan Medical School	Worcester	Massachusetts	01655	Not yet recruiting
Oncology Hematology West P.C. dba Nebraska Cancer - Methodist	Omaha	Nebraska	68114	Recruiting
Oncology Hematology West P.C. dba Nebraska Cancer Specialists	Omaha	Nebraska	68130	Recruiting
MSK Basking Ridge	Basking Ridge	New Jersey	07920	Recruiting
MSK Commack	Commack	New York	11725	Recruiting
Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy	Long Island City	New York	11101	Recruiting
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).	New York	New York	10021	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06215118, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 4, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06215118 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →